Articles related to WOMEN'S HEALTH
New Studies Analyze Risk Factors, Treatments for Afib
A UK study reports that a history of irregular menstrual cycle was associated with higher risk for afib in women. A finding from the Vitamin D and Omega 3 Trial (VITAL) Rhythm Study reveals that when controlled for height and body size, women are at higher risk than men for afib, suggesting that biological sex and body size account for much of the protective effect of female sex. And as separately reported, early rhythm control is associated with lower risk for CV events as compared to usual care.
Cardiology September 13th 2022
How Large Breasts Changed Medicine Forever – The history of sound in medicine
Watch the video podcast filmed in Paris or take the fast route and read the transcript.Rohin Francis, MBBS, takes a history trip with Adam Rodman, MD, of “Bedside Rounds”fame into the history of sound as a diagnostic tool.
Cardiology August 23rd 2022
Young Women and Anal Sex
Anal intercourse is becoming more common among heterosexual couples. In the US, 30-44% of men and women report experience of anal sex. There are a host ofnegative health implications, especially for women, that should be communicatedespecially so patients can make truly informed decisions.
Family Medicine/General Practice August 17th 2022
Why Experts Should Rethink the Cookie Theft Picture for Stroke Evaluation
Since 1972, clinicians have used the Cookie Theft image to assist them diagnose speech and language problems as well as spatial and visual anomalies. However, a position presented in the Journal of the American Medical Association – Neurology suggests that frequent exposure to the Cookie Theft image may reduce patients’ self-confidence and undermine their sense of belonging and trust.
Neurology August 8th 2022
Diving into Developments in Ovarian Cancer Detection
Dr. Janos Tanyi, Associate Professor of Obstetrics and Gynecology at the Hospital of the University of Pennsylvania, is joined by Dr. Charles Turck to discuss fluorescence-guided, intraoperative imaging as well as a new imaging drug to help physicians better detect ovarian cancer.
Obstetrics & Gynecology August 2nd 2022
Fuzuloparib Maintenance Therapy in Patients with Platinum-Sensitive, Recurrent Ovarian Carcinoma (FZOCUS-2): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Trial
This phase III trial evaluated the PARP inhibitor fuzuloparib versus placebo as a maintenance treatment after second- or later-line platinum-based chemotherapy in patients with high-grade, platinum-sensitive, recurrent ovarian cancer. Two-hundred-fifty-two (252) patients were randomly assigned to the fuzuloparib (n = 167) or placebo (n = 85). Twice daily oral fuzuloparib as maintenance therapy was superior to placebo in PFS improvement. Further, benefit was observed both in patients with germline BRCA 1/2 mutations and in those without mutations.
Oncology, Medical August 2nd 2022